Positions

Selected Publications

Academic Article

Year Title Altmetric
2019 ReplyArthritis and Rheumatology.  71:1771-1772. 2019
2019 Reply.Arthritis and Rheumatology.  71:1771-1772. 2019
2019 Characteristics of older adults using patient web portals to view their DXA resultsBMC Medical Informatics and Decision Making.  19. 2019
2019 Race Plays a Role in the Knowledge, Attitudes, and Beliefs of Women with OsteoporosisJournal of Racial and Ethnic Health Disparities.  6:707-718. 2019
2019 A Qualitative Study of the Postoperative Pain Management Educational Needs of Total Joint Replacement PatientsPain Management Nursing.  20:345-351. 2019
2019 Long-Term Safety of Rituximab in Patients With Rheumatoid Arthritis: Results of a Five-Year Observational StudyArthritis Care and Research.  71:993-1003. 2019
2019 Vascular Consequences of Hyperuricemia and HypouricemiaRheumatic Disease Clinics of North America.  45:453-464. 2019
2019 Cost-Effectiveness of Osteoporosis Screening Using Biomechanical Computed Tomography for Patients With a Previous Abdominal CTJournal of Bone and Mineral Research.  34:1229-1239. 2019
2019 Denosumab Versus Risedronate in Glucocorticoid-Induced Osteoporosis: Final Results of a Twenty-Four–Month Randomized, Double-Blind, Double-Dummy TrialArthritis and Rheumatology.  71:1174-1184. 2019
2019 Glucocorticoid-induced osteoporosis updateCurrent Opinion in Rheumatology.  31:388-393. 2019
2019 Osteoporosis Pathophysiology, Epidemiology, and Screening in Rheumatoid ArthritisCurrent Rheumatology Reports.  21. 2019
2019 Comparison of an interactive voice response system and smartphone application in the identification of gout flaresArthritis Research.  21. 2019
2019 Changes in Dkk-1, sclerostin, and RANKL serum levels following discontinuation of long-term denosumab treatment in postmenopausal womenBONE.  123:191-195. 2019
2019 Glucocorticoid-induced osteoporosis: 2019 concise clinical reviewOsteoporosis International.  30:1145-1156. 2019
2019 Changing rates in fracture trends are temporally associated with declining testing and treatment: reality or ecologic fallacy?Current Opinion in Rheumatology.  31:316-320. 2019
2019 Individualized decision aid for diverse women with lupus nephritis (IDEA-WON): A randomized controlled trialPLoS Medicine.  16. 2019
2019 Sex differences in osteoporosis self-efficacy among community-residing older adults presenting for DXAOsteoporosis International.  30:1033-1041. 2019
2019 Tools and Methods for Real-World Evidence Generation: Pragmatic Trials, Electronic Consent, and Data LinkagesRheumatic Disease Clinics of North America.  45:275-289. 2019
2019 Adherence and Outcomes with Urate-Lowering Therapy: A Site-Randomized TrialAmerican Journal of Medicine.  132:354-361. 2019
2019 Gout, Hyperuricemia, and Crystal-Associated Disease Network Consensus Statement Regarding Labels and Definitions for Disease Elements in GoutArthritis Care and Research.  71:427-434. 2019
2019 Reduction of Hip and Other Fractures in Patients Receiving Teriparatide in Real-World Clinical Practice: Integrated Analysis of Four Prospective Observational StudiesCalcified Tissue International.  104:193-200. 2019
2019 Recommendations for the conduct of economic evaluations in osteoporosis: outcomes of an experts’ consensus meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the US branch of the International Osteoporosis FoundationOsteoporosis International.  30:45-57. 2019
2019 Balancing benefits and risks in the era of biologicsTherapeutic Advances in Musculoskeletal Disease.  11. 2019
2019 Consensus Statement on the Use of Bone Turnover Markers for Short-Term Monitoring of Osteoporosis Treatment in the Asia-Pacific RegionJournal of Clinical Densitometry2019
2019 Design, analysis, power, and sample size calculation for three-phase interrupted time series analysis in evaluation of health policy interventionsJournal of Evaluation in Clinical Practice2019
2019 Efficacy and Safety of Febuxostat Extended and Immediate Release in Patients With Gout and Renal Impairment: A Phase III Placebo-Controlled StudyArthritis and Rheumatology.  71:143-153. 2019
2019 Glucocorticoid-induced osteoporosis: from clinical trials to clinical practiceTherapeutic Advances in Musculoskeletal Disease.  11. 2019
2019 Integrated safety studies of the urate reabsorption inhibitor lesinurad in treatment of goutRheumatology.  58:61-69. 2019
2019 Patterns of glucocorticoid prescribing and provider-level variation in a commercially insured incident rheumatoid arthritis population: A retrospective cohort studySeminars in Arthritis and Rheumatism2019
2018 Diet and exercise changes following bone densitometry in the Patient Activation After DXA Result Notification (PAADRN) studyArchives of Osteoporosis.  13. 2018
2018 Importance of Recent Fracture as Predictor of Imminent Fracture RiskCurrent Osteoporosis Reports.  16:738-745. 2018
2018 Medical Rehabilitation: Guidelines to Advance the Field With High-Impact Clinical TrialsArchives of Physical Medicine and Rehabilitation.  99:2637-2648. 2018
2018 The prevalence of overtreatment of osteoporosis: results from the PAADRN trialArchives of Osteoporosis.  13. 2018
2018 Correction to: Hip fracture trends in the United States, 2002 to 2015 (Osteoporosis International, (2018), 29, 3, (717-722), 10.1007/s00198-017-4345-0)Osteoporosis International.  29:2583. 2018
2018 How to use bisphosphonates safely and optimallyRheumatology.  57:1875-1876. 2018
2018 Is Rheumatoid Arthritis a Cardiovascular Risk-Equivalent to Diabetes Mellitus?Arthritis Care and Research.  70:1694-1699. 2018
2018 Real-world effectiveness of teriparatide on fracture reduction in patients with osteoporosis and comorbidities or risk factors for fractures: Integrated analysis of 4 prospective observational studiesBONE.  116:58-66. 2018
2018 Glucocorticoid Exposure and Fracture Risk in a Cohort of US Patients With Selected ConditionsJournal of Bone and Mineral Research.  33:1881-1888. 2018
2018 Opioids vs nonopioids for chronic back, hip, or knee painJournal of the American Medical Association.  320:508. 2018
2018 Moving Career Development Upstream: Evaluation of a Course for Internal Medicine Trainees Contemplating Career Pathways in Academic MedicineSouthern Medical Journal.  111:471-475. 2018
2018 Hypophosphatemia in the setting of metabolic bone disease: case reports and diagnostic algorithmTherapeutic Advances in Musculoskeletal Disease.  10:151-156. 2018
2018 Improving drug adherence in osteoporosis: an update on more recent studiesTherapeutic Advances in Musculoskeletal Disease.  10:141-149. 2018
2018 Risk of malignancy associated with paediatric use of tumour necrosis factor inhibitorsAnnals of the Rheumatic Diseases.  77:1012-1016. 2018
2018 A Performing Arts Intervention Improves Cognitive Dysfunction in 50 Hospitalized Older Adults.Innovation in Aging.  2:igy013. 2018
2018 Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority studyLancet Diabetes and Endocrinology.  6:445-454. 2018
2018 Efficacy and safety of febuxostat extended release and immediate release in patients with gout and moderate renal impairment: Phase II placebo-controlled studyArthritis Research.  20. 2018
2018 Evaluation of a Multimodal, Direct-to-Patient Educational Intervention Targeting Barriers to Osteoporosis Care: A Randomized Clinical TrialJournal of Bone and Mineral Research.  33:763-772. 2018
2018 Use of Scribes for Documentation Assistance in Rheumatology and Endocrinology Clinics: Impact on Clinic Workflow and Patient and Physician SatisfactionJCR: Journal of Clinical Rheumatology.  24:116-121. 2018
2018 Cardiovascular safety of febuxostat or allopurinol in patients with goutNew England Journal of Medicine.  378:1200-1210. 2018
2018 Biomarker-related risk for myocardial infarction and serious infections in patients with rheumatoid arthritis: a population-based studyAnnals of the Rheumatic Diseases.  77:386-392. 2018
2018 Brief Report: Validation of a Definition of Flare in Patients With Established GoutArthritis and Rheumatology.  70:462-467. 2018
2018 Hip fracture trends in the United States, 2002 to 2015Osteoporosis International.  29:717-722. 2018
2018 Development and Pilot Testing of Multimedia Patient Education Tools for Patients With Knee Osteoarthritis, Osteoporosis, and Rheumatoid ArthritisArthritis Care and Research.  70:213-220. 2018
2018 Just the FRAX: Management of Glucocorticoid-Induced OsteoporosisGastroenterology.  154:748-750. 2018
2018 Taking an Interdisciplinary Approach to Understanding and Improving Medication AdherenceJournal of General Internal Medicine.  33:136-138. 2018
2018 Romosozumab versus Alendronate and Fracture Risk in Women with OsteoporosisNew England Journal of Medicine.  378:195-196. 2018
2018 ACTIVExtend: 24 Months of alendronate after 18 months of abaloparatide or placebo for postmenopausal osteoporosisJournal of Clinical Endocrinology and Metabolism.  103:2949-2957. 2018
2018 Healthcare Providers' Recommendations for Physical Activity among US Arthritis Population: A Cross-Sectional Analysis by Race/Ethnicity.Arthritis.  2018:2807035. 2018
2018 Routine use of quantitative disease activity measurements among us rheumatologists: Implications for treat-to-target management strategies in rheumatoid arthritisJournal of Rheumatology.  45:40-44. 2018
2017 Effects of Febuxostat in Early Gout: A Randomized, Double-Blind, Placebo-Controlled StudyArthritis and Rheumatology.  69:2386-2395. 2017
2017 Lesinurad monotherapy in gout patients intolerant to a xanthine oxidase inhibitor: A 6 month phase 3 clinical trial and extension studyRheumatology.  56:2170-2178. 2017
2017 Screening questions for nonsteroidal anti-inflammatory drug risk knowledgeJournal of Patient Safety.  13:217-222. 2017
2017 Self-perception of fracture risk: what can it tell us?Osteoporosis International.  28:3495-3500. 2017
2017 Validity, reliability, and responsiveness to change of the “Osteoporosis and You” knowledge scaleOsteoporosis International.  28:3379-3388. 2017
2017 Response to the American College of Physicians Osteoporosis Guideline, 2017 UpdateArthritis and Rheumatology.  69:2097-2101. 2017
2017 Serious Infections in Childhood-Onset Systemic Lupus Erythematosus: Using Administrative Claims Data to Investigate Disease OutcomesArthritis Care and Research.  69:1617-1619. 2017
2017 The impact of the new National Bone Health Alliance (NBHA) diagnostic criteria on the prevalence of osteoporosis in the United States: supplementary presentationOsteoporosis International.  28:3283-3284. 2017
2017 Romosozumab or alendronate for fracture prevention in women with osteoporosisNew England Journal of Medicine.  377:1417-1427. 2017
2017 Activating Patients With a Tailored Bone Density Test Results Letter and Educational Brochure: the PAADRN Randomized Controlled TrialJournal of Clinical Densitometry.  20:464-471. 2017
2017 Risk of Hypersensitivity to Biologic Agents Among Medicare Patients With Rheumatoid ArthritisArthritis Care and Research.  69:1526-1534. 2017
2017 The cost of a patient activation intervention for achieving successful outcomes: results from the PAADRN randomized controlled trialOsteoporosis International.  28:3061-3066. 2017
2017 The effects of a patient activation intervention on smoking and excessive drinking cessations: results from the PAADRN randomized controlled trialOsteoporosis International.  28:3055-3060. 2017
2017 Changing Trends in Opioid Use Among Patients With Rheumatoid Arthritis in the United StatesArthritis and Rheumatology.  69:1733-1740. 2017
2017 Discordant American College of Physicians and international rheumatology guidelines for gout management: Consensus statement of the Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN)Nature Reviews Rheumatology.  13:561-568. 2017
2017 Regional Differences in Incident Prefrailty and FrailtyJournal of Women's Health.  26:992-998. 2017
2017 Erratum to: Assessing the feasibility of the Effectiveness of Discontinuing Bisphosphonates trial: a pilot study (Osteoporosis International, (2017), 28, 8, (2495-2503), 10.1007/s00198-017-4073-5)Osteoporosis International.  28:2505. 2017
2017 Longterm effectiveness of herpes zoster vaccine among patients with autoimmune and inflammatory diseasesJournal of Rheumatology.  44:1083-1087. 2017
2017 Patient-reported reasons for nonadherence to recommended osteoporosis pharmacotherapyJournal of the American Pharmaceutical Association (Washington,D.C. : 1996).  57:503-509. 2017
2017 Management of goutAnnals of Internal Medicine.  166:855. 2017
2017 Assessing the feasibility of the Effectiveness of Discontinuing Bisphosphonates trial: a pilot studyOsteoporosis International.  1-9. 2017
2017 ReplyArthritis and Rheumatology.  69:1122. 2017
2017 The impact of the new National Bone Health Alliance (NBHA) diagnostic criteria on the prevalence of osteoporosis in the USAOsteoporosis International.  28:1225-1232. 2017
2017 Treat-To-Target (T2T) recommendations for goutAnnals of the Rheumatic Diseases.  76:632-638. 2017
2017 Sex differences in gout characteristics: Tailoring care for women and menBMC Musculoskeletal Disorders.  18. 2017
2017 Addressing the Crisis in the Treatment of Osteoporosis: A Path ForwardJournal of Bone and Mineral Research.  32:424-430. 2017
2017 Development of a Glucocorticoid Toxicity Index (GTI) using multicriteria decision analysisAnnals of the Rheumatic Diseases.  76:543-546. 2017
2017 EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 updateAnnals of the Rheumatic Diseases.  76:960-977. 2017
2017 Evaluation of a "Just-in-Time" Nurse Consultation on Bone Health: A Pilot Randomized Controlled TrialThe Permanente Journal.  21. 2017
2017 Lesinurad Combined With Allopurinol: A Randomized, Double-Blind, Placebo-Controlled Study in Gout Patients With an Inadequate Response to Standard-of-Care Allopurinol (a US-Based Study)Arthritis and Rheumatology.  69:203-212. 2017
2017 Racial Differences and Disparities in Osteoporosis-related Bone Health: Results from the PAADRN Randomized Controlled TrialMedical Care.  55:561-568. 2017
2017 Understanding Preferences for Osteoporosis Information to Develop an Osteoporosis Patient Education BrochureThe Permanente Journal.  21. 2017
2016 A multi-modal intervention for Activating Patients at Risk for Osteoporosis (APROPOS): Rationale, design, and uptake of online study intervention materialContemporary Clinical Trials Communications.  4:14-24. 2016
2016 Understanding practice-based research participation: The differing motivations of engaged vs. non-engaged clinicians in pragmatic clinical trialsContemporary Clinical Trials Communications.  4:136-140. 2016
2016 Patient-activation and guideline-concordant pharmacological treatment after bone density testing: the PAADRN randomized controlled trialOsteoporosis International.  27:3513-3524. 2016
2016 The National Osteoporosis Foundation’s methods and processes for developing position statementsArchives of Osteoporosis.  11. 2016
2016 Cost-effectiveness of Low-dose Submicron Diclofenac Compared With Generic DiclofenacClinical Therapeutics.  38:2418-2429. 2016
2016 Evaluating the effectiveness of a patient storytelling DVD intervention to encourage physician-patient communication about nonsteroidal anti-inflammatory drug (NSAID) usePatient Education and Counseling.  99:1837-1844. 2016
2016 Glucocorticoid exposure and fracture risk in patients with new-onset rheumatoid arthritisOsteoporosis International.  27:3239-3249. 2016
2016 Combining Computed Tomography-Based Bone Density Assessment with FRAX Screening in Men with Prostate CancerJournal of Clinical Densitometry.  19:430-435. 2016
2016 Comparative effects of biologics on cardiovascular risk among older patients with rheumatoid arthritisAnnals of the Rheumatic Diseases.  75:1813-1818. 2016
2016 ReplyArthritis and Rheumatology.  68:2564. 2016
2016 Socio-demographic differences in risk information seeking sources for non-steroidal anti-inflammatory drugs (NSAIDS)International Journal of Medical Informatics.  94:222-227. 2016
2016 Patient's experience with subcutaneous and oral methotrexate for the treatment of rheumatoid arthritisBMC Musculoskeletal Disorders.  17. 2016
2016 The risk of hospitalized infection following initiation of biologic agents versus methotrexate in the treatment of juvenile idiopathic arthritisArthritis Research.  18. 2016
2016 Analysis of health care claims during the peri-transfer stage of transition from pediatric to adult care among juvenile idiopathic arthritis patientsPediatric Rheumatology.  14. 2016
2016 Rationale and design of the randomized evaluation of an Ambulatory Care Pharmacist-Led Intervention to Optimize Urate Lowering Pathways (RAmP-UP) StudyControlled Clinical Trials.  50:106-115. 2016
2016 Risk of Herpes Zoster in Autoimmune and Inflammatory Diseases: Implications for VaccinationArthritis and Rheumatology.  68:2328-2337. 2016
2016 The effects of urate lowering therapy on inflammation, endothelial function, and blood pressure (SURPHER) study design and rationaleControlled Clinical Trials.  50:238-244. 2016
2016 Trabecular Bone Score in Patients With Chronic Glucocorticoid Therapy–Induced Osteoporosis Treated With Alendronate or TeriparatideArthritis and Rheumatology.  68:2122-2128. 2016
2016 Effects of a DXA result letter on satisfaction, quality of life, and osteoporosis knowledge: A randomized controlled trialBMC Musculoskeletal Disorders.  17. 2016
2016 A pragmatic randomized trial comparing tablet computer informed consent to traditional paper-based methods for an osteoporosis studyContemporary Clinical Trials Communications.  3:32-38. 2016
2016 Impact of Febuxostat on Renal Function in Gout Patients With Moderate-to-Severe Renal ImpairmentArthritis and Rheumatology.  68:2035-2043. 2016
2016 Increase in Fracture Risk Following Unintentional Weight Loss in Postmenopausal Women: The Global Longitudinal Study of Osteoporosis in WomenJournal of Bone and Mineral Research.  31:1466-1472. 2016
2016 ReplyArthritis and Rheumatology.  68:1316-1318. 2016
2016 ReplyArthritis Care and Research.  68:725-726. 2016
2016 Balancing benefits and risks of glucocorticoids in rheumatic diseases and other inflammatory joint disorders: new insights from emerging data. An expert consensus paper from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO)Aging Clinical and Experimental Research.  28. 2016
2016 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid ArthritisArthritis and Rheumatology.  68:1-26. 2016
2016 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid ArthritisArthritis and Rheumatology.  68:1-26. 2016
2016 Comparative Risk of Hospitalized Infection Associated with Biologic Agents in Rheumatoid Arthritis Patients Enrolled in MedicareArthritis and Rheumatology.  68:56-66. 2016
2016 Glucocorticoid-induced OsteoporosisRheumatic Disease Clinics of North America.  42:177-189. 2016
2015 The comparative effectiveness of biologics among older adults and disabled rheumatoid arthritis patients in the Medicare populationBritish Journal of Clinical Pharmacology.  80:1447-1457. 2015
2015 2015 Gout Classification Criteria: An American College of Rheumatology/European League Against Rheumatism Collaborative InitiativeArthritis and Rheumatology.  67:2557-2568. 2015
2015 2015 Gout classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiativeAnnals of the Rheumatic Diseases.  74:1789-1798. 2015
2015 Bisphosphonates and glucocorticoid-induced osteoporosis: consEndocrine.  49:628-634. 2015
2015 The validity of claims-based algorithms to identify serious hypersensitivity reactions and osteonecrosis of the jawPLoS ONE.  10. 2015
2015 Development of EULAR recommendations for the reporting of clinical trial extension studies in rheumatologyAnnals of the Rheumatic Diseases.  74:963-969. 2015
2015 An internet-based controlled trial aimed to improve osteoporosis prevention among chronic glucocorticoid usersJournal of Rheumatology.  42:1478-1483. 2015
2015 Balancing the benefits and risks of low-dose glucocorticoid in rheumatoid arthritisActa Reumatologica Portuguesa.  2015:10-22. 2015
2015 Balancing the benefits and risks of low-dose glucocorticoid in rheumatoid arthritis.Acta Reumatologica Portuguesa.  40:10-22. 2015
2015 Evaluating and mitigating fracture risk in established rheumatoid arthritisBest Practice and Research: Clinical Rheumatology.  29:614-627. 2015
2015 Fractures and mortality in relation to different osteoporosis treatmentsClinical and Experimental Rheumatology.  33:302-309. 2015
2015 Impact of biologic agents with and without concomitant methotrexate and at reduced doses in older rheumatoid arthritis patientsArthritis Care and Research.  67:624-632. 2015
2015 Modifiable factors associated with allopurinol adherence and outcomes among patients with gout in an integrated healthcare systemJournal of Rheumatology.  42:504-512. 2015
2015 Risk of hospitalized infection among rheumatoid arthritis patients concurrently treated with a biologic agent and denosumabArthritis and Rheumatology.  67:1456-1464. 2015
2015 Risks of herpes zoster in patients with rheumatoid arthritis according to biologic disease-modifying therapyArthritis Care and Research.  67:731-736. 2015
2015 What is the relationship between morning symptoms and measures of disease activity in patients with rheumatoid arthritis?Arthritis Care and Research.  67:1202-1209. 2015
2014 The safety of low-dose glucocorticoids in rheumatic diseases: Results from observational studiesNeuroimmunomodulation.  22:72-82. 2014
2014 Non-viral opportunistic infections in new users of tumour necrosis factor inhibitor therapy: Results of the SAfety assessment of biologic ThERapy (SABER) studyAnnals of the Rheumatic Diseases.  73:1942-1948. 2014
2014 The recent prevalence of osteoporosis and low bone mass in the United States based on bone mineral density at the femoral neck or lumbar spineJournal of Bone and Mineral Research.  29:2520-2526. 2014
2014 Use of Oral and Subcutaneous Methotrexate in Rheumatoid Arthritis Patients in the United StatesArthritis Care and Research.  66:1604-1611. 2014
2014 Developing a bone mineral density test result letter to send to patients: A mixed-methods studyPatient Preference and Adherence.  8:827-841. 2014
2014 Relationship between diclofenac dose and risk of gastrointestinal and cardiovascular events: Meta-regression based on two systematic literature reviewsClinical Therapeutics.  36:906-917. 2014
2014 Patterns and predictors of osteoporosis medication discontinuation and switching among Medicare beneficiariesBMC Musculoskeletal Disorders.  15. 2014
2014 Death, debility, and destitution following hip fractureJournals of Gerontology, Series A.  69 A:346-353. 2014
2014 Obesity, health-care utilization, and health-related quality of life after fracture in postmenopausal women: Global longitudinal study of osteoporosis in women (GLOW)Calcified Tissue International.  94:223-231. 2014
2014 Relationship of weight, height, and body mass index with fracture risk at different sites in postmenopausal women: The global longitudinal study of osteoporosis in women (GLOW)Journal of Bone and Mineral Research.  29:487-493. 2014
2014 Use of health plan combined with registry data to predict clinical trial recruitmentClinical Trials.  11:96-101. 2014
2014 A group-randomized trial of shared decision making for non-steroidal anti-inflammatory drug risk awareness: Primary Results and lessons learnedJournal of Evaluation in Clinical Practice.  20:638-648. 2014
2014 Bisphosphonates and hip and nontraumatic subtrochanteric femoral fractures in the veterans health administrationJCR: Journal of Clinical Rheumatology.  20:357-362. 2014
2014 Bone safety of low-dose glucocorticoids in rheumatic diseasesAnnals of the New York Academy of Sciences.  1318:55-64. 2014
2014 Disease-specific perception of fracture risk and incident fracture rates: GLOW cohort studyOsteoporosis International.  25:85-95. 2014
2014 Effect of self-referral on bone mineral density testing and osteoporosis treatmentMedical Care.  52:743-750. 2014
2014 Empirically based composite fracture prediction model from the Global Longitudinal Study of Osteoporosis in Postmenopausal Women (GLOW)Journal of Clinical Endocrinology and Metabolism.  99:817-826. 2014
2014 Fracture mortality: Associations with epidemiology and osteoporosis treatmentNature Reviews Endocrinology.  10:592-602. 2014
2014 Improving bone mineral density reporting to patients with an illustration of personal fracture riskBMC Medical Informatics and Decision Making.  14. 2014
2014 International management of bone health in glucocorticoid-exposed individuals in the observational GLOW studyOsteoporosis International.  26:419-420. 2014
2014 OMERACT endorsement of measures of outcome for studies of acute goutJournal of Rheumatology.  41:569-573. 2014
2014 RE: Drug risk assessment and data reusePharmacoepidemiology and Drug Safety.  23:109-110. 2014
2014 Risk factors for treatment failure with antiosteoporosis medication: The global longitudinal study of osteoporosis in women (GLOW)Journal of Bone and Mineral Research.  29:260-267. 2014
2014 Risk of hospitalized bacterial infections associated with biologic treatment among US veterans with rheumatoid arthritisArthritis Care and Research.  66:990-997. 2014
2014 The clinical diagnosis of osteoporosis: A position statement from the National Bone Health Alliance Working GroupOsteoporosis International.  25:1439-1443. 2014
2014 Trends in the utilization and outcomes of medicare patients hospitalized for hip fracture, 2000-2008Journal of Aging and Health.  26:360-379. 2014
2014 Use of pharmacologic agents for the primary prevention of osteoporosis among older women with low bone massOsteoporosis International.  25:317-324. 2014
2013 When, where and how osteoporosis-associated fractures occur: An analysis from the global longitudinal study of osteoporosis in women (GLOW)PLoS ONE.  8. 2013
2013 Glucocorticoid-related bone changes from endogenous or exogenous glucocorticoidsCurrent Opinion in Endocrinology and Diabetes.  20:510-516. 2013
2013 Prevention and treatment of bone changes associated with exposure to glucocorticoidsCurrent Osteoporosis Reports.  11:341-347. 2013
2013 Tumor necrosis factor, tuberculosis, testing, and treatment: Teeing up the questionsArthritis Care and Research.  65:1719-1721. 2013
2013 Tumor necrosis factor, tuberculosis, testing, and treatment: teeing up the questions.Arthritis Care and Research.  65:1719-1721. 2013
2013 Challenges in defining quality of care for glucocorticoid-induced osteoporosis: Defending good against perfectJournal of Rheumatology.  40:1640-1642. 2013
2013 Multimodal intervention to improve osteoporosis care in home health settings: Results from a cluster randomized trialOsteoporosis International.  24:2555-2560. 2013
2013 Re-using Mini-Sentinel data following rapid assessments of potential safety signals via modular analytic programsPharmacoepidemiology and Drug Safety.  22:1036-1045. 2013
2013 Seizure occurrence following nonoptimal anticonvulsant medication management during the transition into the hospitalJournal of Child Neurology.  28:1250-1258. 2013
2013 Serum urate association with hypertension in young adults: Analysis from the Coronary Artery Risk Development in Young Adults cohortAnnals of the Rheumatic Diseases.  72:1321-1327. 2013
2013 Serum urate levels and consumption of common beverages and alcohol among chinese in SingaporeArthritis Care and Research.  65:1432-1440. 2013
2013 Study design considerations for a large simple trial of bisphosphonatesCurrent Opinion in Rheumatology.  25:517-523. 2013
2013 Rapid assessment of cardiovascular risk among users of smoking cessation drugs within the US Food and Drug Administration's Mini-sentinel ProgramJAMA Internal Medicine.  173:817-819. 2013
2013 Brief report: Incidence of selected opportunistic infections among children with juvenile idiopathic arthritisArthritis and Rheumatism.  65:1384-1389. 2013
2013 ReplyArthritis Care and Research.  65:832-833. 2013
2013 A close examination of healthcare expenditures related to fracturesJournal of Bone and Mineral Research.  28:816-820. 2013
2013 Association between anti-TNF-α therapy and interstitial lung diseasePharmacoepidemiology and Drug Safety.  22:394-402. 2013
2013 Association between osteoporosis treatment change and adherence, incident fracture, and total healthcare costs in a Medicare Advantage Prescription Drug planOsteoporosis International.  24:1195-1206. 2013
2013 Gout-related health care utilization in US emergency departments, 2006 through 2008Arthritis Care and Research.  65:571-577. 2013
2013 Osteoporosis Diagnosis and Medical TreatmentOrthopedic Clinics of North America.  44:125-135. 2013
2013 Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zosterJournal of the American Medical Association.  309:887-895. 2013
2013 Anticonvulsant medication errors in children with epilepsy during the home-to-hospital transitionJournal of Child Neurology.  28:314-320. 2013
2013 Low-dose prednisone chronotherapy for rheumatoid arthritis: A randomised clinical trial (CAPRA-2)Annals of the Rheumatic Diseases.  72:204-210. 2013
2013 Patterns of osteoporosis treatment change and treatment discontinuation among commercial and Medicare Advantage Prescription Drug members in a national health planJournal of Evaluation in Clinical Practice.  19:50-59. 2013
2013 Physicians' explanations for apparent gaps in the quality of rheumatology care: Results from the US Medicare Physician Quality Reporting SystemArthritis Care and Research.  65:235-243. 2013
2013 Cardiovascular risk in rheumatoid arthritis: Comparing tnf-α blockade with nonbiologic DMARDsAmerican Journal of Medicine.  126:730.e9-730.e17. 2013
2013 Choosing wisely: The American College of Rheumatology's top 5 list of things physicians and patients should questionArthritis Care and Research.  65:329-339. 2013
2013 Generic alendronate use among medicare beneficiaries: Are part d data complete?Pharmacoepidemiology and Drug Safety.  22:55-63. 2013
2013 Initiation of anti-TNF therapy and the risk of optic neuritis: From the safety assessment of biologic ThERapy (SABER) studyAmerican Journal of Ophthalmology.  155:183-189.e1. 2013
2013 Non-hip, non-spine fractures drive healthcare utilization following a fracture: The Global Longitudinal Study of Osteoporosis in Women (GLOW)Osteoporosis International.  24:59-67. 2013
2013 Osteopenia: Debates and dilemmasCurrent Rheumatology Reports.  15. 2013
2013 The PAADRN Study: A design for a randomized controlled practical clinical trial to improve bone healthControlled Clinical Trials.  34:90-100. 2013
2013 Trends in the use of biologic agents among rheumatoid arthritis patients enrolled in the US medicare programArthritis Care and Research.  65:1743-1751. 2013
2013 Tumor necrosis factor α inhibitor therapy and cancer risk in chronic immune-mediated diseasesArthritis and Rheumatism.  65:48-58. 2013
2013 Using tablet computers compared to interactive voice response to improve subject recruitment in osteoporosis pragmatic clinical trials: Feasibility, satisfaction, and sample sizePatient Preference and Adherence.  7:517-523. 2013
2012 A randomized trial of a mailed intervention and self-scheduling to improve osteoporosis screening in postmenopausal womenJournal of Bone and Mineral Research.  27:2603-2610. 2012
2012 Association between anti-TNF-α therapy and all-cause mortalityPharmacoepidemiology and Drug Safety.  21:1311-1320. 2012
2012 Burden of non-hip, non-vertebral fractures on quality of life in postmenopausal women: The Global Longitudinal study of Osteoporosis in Women (GLOW)Osteoporosis International.  23:2863-2871. 2012
2012 Does medication adherence itself confer fracture protection? An investigation of the healthy adherer effect in observational dataArthritis Care and Research.  64:1855-1863. 2012
2012 Preliminary Competencies for Comparative Effectiveness ResearchClinical and Translational Science.  5:476-479. 2012
2012 Improving the efficiency and effectiveness of pragmatic clinical trials in older adults in the United StatesControlled Clinical Trials.  33:1211-1216. 2012
2012 Recent trends in hip fracture rates by race/ethnicity among older US adultsJournal of Bone and Mineral Research.  27:2325-2332. 2012
2012 Short-term and long-term safety of glucocorticoids in rheumatoid arthritisBulletin- Nyu Hospital for Joint Diseases.  70. 2012
2012 ReplyArthritis Care and Research.  64:1623-1624. 2012
2012 Rilonacept (interleukin-1 trap) for prevention of gout flares during initiation of uric acid-lowering therapy: Results from a phase III randomized, double-blind, placebo-controlled, confirmatory efficacy studyArthritis Care and Research.  64:1462-1470. 2012
2012 Use of a disease risk score to compare serious infections associated with anti-tumor necrosis factor therapy among high-versus lower-risk rheumatoid arthritis patientsArthritis Care and Research.  64:1480-1489. 2012
2012 Acknowledgments for "best practices in systems-based interventions to reduce the burden of fractures" (Osteoporosis International Volume 22, Supplement 3, August 2011)Osteoporosis International.  23:2393-2394. 2012
2012 Rates of hospitalized bacterial infection associated with juvenile idiopathic arthritis and its treatmentArthritis and Rheumatism.  64:2773-2780. 2012
2012 Regional and age-related variations in the proportions of hip fractures and major fractures among postmenopausal women: The Global Longitudinal Study of Osteoporosis in WomenOsteoporosis International.  23:2179-2188. 2012
2012 The effect of teriparatide compared with risedronate on reduction of back pain in postmenopausal women with osteoporotic vertebral fracturesOsteoporosis International.  23:2141-2150. 2012
2012 Association between Vaccination for Herpes Zoster and Risk of Herpes Zoster Infection among Older Patients with Selected Immune-Mediated DiseasesJournal of the American Medical Association.  308:43-49. 2012
2012 Adherence with intravenous zoledronate and intravenous ibandronate in the United States medicare populationArthritis Care and Research.  64:1054-1060. 2012
2012 Effect of co-morbidities on fracture risk: Findings from the Global Longitudinal Study of Osteoporosis in Women (GLOW)BONE.  50:1288-1293. 2012
2012 From fracture risk prediction to evaluating fracture patterns: Recent advances in the epidemiology of osteoporosisCurrent Rheumatology Reports.  14:205-211. 2012
2012 Mortality due to coronary heart disease and kidney disease among middle-aged and elderly men and women with gout in the Singapore Chinese Health StudyAnnals of the Rheumatic Diseases.  71:924-928. 2012
2012 2012 update of the 2008 American college of rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritisArthritis Care and Research.  64:635-639. 2012
2012 Rheumatoid arthritis disease activity measures: American college of rheumatology recommendations for use in clinical practiceArthritis Care and Research.  64:640-647. 2012
2012 Central DXA utilization shifts from office-based to hospital-based settings among medicare beneficiaries in the wake of reimbursement changesJournal of Bone and Mineral Research.  27:858-864. 2012
2012 Incidence and risk factors for progressive multifocal leukoencephalopathy among patients with selected rheumatic diseasesArthritis Care and Research.  64:612-615. 2012
2012 Corrigendum to "Bisphosphonates and glucocorticoid osteoporosis in men: Results of a randomized controlled trial comparing zoledronic acid with risedronate" [Bone 50 (2012) 289-295]BONE.  50:811. 2012
2012 Post hoc analysis of a single IV infusion of zoledronic acid versus daily oral risedronate on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosisOsteoporosis International.  23:1083-1090. 2012
2012 Previous fractures at multiple sites increase the risk for subsequent fractures: The global longitudinal study of osteoporosis in womenJournal of Bone and Mineral Research.  27:645-653. 2012
2012 Drug treatment of hyperuricemia to prevent cardiovascular outcomes: Are we there yet?American Journal of Cardiovascular Drugs.  12:1-6. 2012
2012 Association between being African-American, serum urate levels and the risk of developing hyperuricemia: Findings from the Coronary Artery Risk Development in Young Adults cohortArthritis Research.  14. 2012
2012 Bisphosphonates and glucocorticoid osteoporosis in men: Results of a randomized controlled trial comparing zoledronic acid with risedronateBONE.  50:289-295. 2012
2012 Developing a provisional definition of flare in patients with established goutArthritis and Rheumatism.  64:1508-1517. 2012
2012 Evaluating comorbidity scores based on health service expendituresMedicare & medicaid research review.  2. 2012
2012 Improving osteoporosis care in high-risk home health patients through a high-intensity interventionControlled Clinical Trials.  33:206-212. 2012
2012 Rates of malignancy associated with juvenile idiopathic arthritis and its treatment.Arthritis and Rheumatism.  64:1263-1271. 2012
2012 ReplyArthritis Care and Research.  64:157-158. 2012
2012 Validation of Diagnostic Codes for Subtrochanteric, Diaphyseal, and Atypical Femoral Fractures Using Administrative Claims DataJournal of Clinical Densitometry.  15:92-102. 2012
2011 Initiation of tumor necrosis factor-αantagonists and the risk of hospitalization for infection in patients with autoimmune diseasesJournal of the American Medical Association.  306:2331-2339. 2011
2011 The safety of low-dose glucocorticoids in rheumatic diseasesClinical and Experimental Rheumatology.  29. 2011
2011 Predicting fractures in an international cohort using risk factor algorithms without BMDJournal of Bone and Mineral Research.  26:2770-2777. 2011
2011 Study design for a comprehensive assessment of biologic safety using multiple healthcare data systemsPharmacoepidemiology and Drug Safety.  20:1199-1209. 2011
2011 Derivation and preliminary validation of an administrative claims-based algorithm for the effectiveness of medications for rheumatoid arthritisArthritis Research.  13. 2011
2011 Is two better than one? Combining antiresorptive and anabolic osteoporosis medicationsCurrent Osteoporosis Reports.  9:109-111. 2011
2011 Regional differences in treatment for osteoporosis. The Global Longitudinal Study of Osteoporosis in Women (GLOW)BONE.  49:493-498. 2011
2011 ReplyArthritis Care and Research.  63:1355. 2011
2011 Long-term safety concerns of antiresorptive therapyRheumatic Disease Clinics of North America.  37:387-400. 2011
2011 Systems-based approaches to osteoporosis and fracture care: Policy and research recommendations from the workgroupsOsteoporosis International.  22. 2011
2011 The comparative risk of serious infections among rheumatoid arthritis patients starting or switching biological agentsAnnals of the Rheumatic Diseases.  70:1401-1406. 2011
2011 Bringing it all together: A novel approach to the development of response criteria for chronic gout clinical trialsJournal of Rheumatology.  38:1467-1470. 2011
2011 Official Positions for FRAX® Clinical Regarding Glucocorticoids: The impact of the Use of Glucocorticoids on the Estimate by FRAX® of the 10 Year Risk of Fracture. From Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX®MJournal of Clinical Densitometry.  14:212-219. 2011
2011 Communicating non-steroidal anti-inflammatory drug risks: Verbal counseling, written medicine information, and patients' risk awarenessPatient Education and Counseling.  83:391-397. 2011
2011 Potential and pitfalls of using large administrative claims data to study the safety of osteoporosis therapiesCurrent Rheumatology Reports.  13:273-282. 2011
2011 Response to Letter to Editor on validation study identifying bacterial infections in rheumatoid arthritis patientsJournal of Clinical Epidemiology.  64:573. 2011
2011 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features.Arthritis Care and Research.  63:465-482. 2011
2011 Erratum: Clinical and demographic factors associated with fractures among older Americans (Osteoporosis International DOI: 10.1007/s00198-010-1300-8)Osteoporosis International.  22:1275-1276. 2011
2011 Should bisphosphonates be used for long-term treatment of glucocorticoid-induced osteoporosis?Arthritis and Rheumatism.  63:325-328. 2011
2011 An observational study of glucocorticoid-induced osteoporosis prophylaxis in a national cohort of male veterans with rheumatoid arthritisOsteoporosis International.  22:305-315. 2011
2011 Clinical and demographic factors associated with fractures among older AmericansOsteoporosis International.  22:1263-1274. 2011
2011 Defining quality of care in rheumatology: The American College of rheumatology white paper on quality measurementArthritis Care and Research.  63:2-9. 2011
2011 Failure to perceive increased risk of fracture in women 55 years and older: The Global Longitudinal Study of Osteoporosis in Women (GLOW)Osteoporosis International.  22:27-35. 2011
2011 Obesity is not protective against fracture in postmenopausal women: GlowAmerican Journal of Medicine.  124:1043-1050. 2011
2011 Which fractures are most attributable to osteoporosis?Journal of Clinical Epidemiology.  64:46-53. 2011
2010 Serum urate and its relationship with alcoholic beverage intake in men and women: Findings from the Coronary Artery Risk Development in Young Adults (CARDIA) cohortAnnals of the Rheumatic Diseases.  69:1965-1970. 2010
2010 Osteoporosis care in the United States after declines in reimbursements for DXAJournal of Clinical Densitometry.  13:352-360. 2010
2010 Cost-effectiveness of multifaceted evidence implementation programs for the prevention of glucocorticoid-induced osteoporosisOsteoporosis International.  21:1573-1584. 2010
2010 Health services utilization after fractures: Evidence from MedicareJournals of Gerontology, Series A.  65 A:1012-1020. 2010
2010 Medication assistance programs: Do all in need benefit equally?Ethnicity and Disease.  20:339-345. 2010
2010 From bone biology to clinical outcome: State of the art and future perspectivesAnnals of the Rheumatic Diseases.  69:1415-1419. 2010
2010 The delivery of evidence-based preventive care for older Americans with arthritisArthritis Research.  12. 2010
2010 Current Opinion in Rheumatology: Editorial introductionsCurrent Opinion in Rheumatology.  22. 2010
2010 Identifying types of nursing facility stays using medicare claims data: An algorithm and validationHealth Services and Outcomes Research Methodology.  10:100-110. 2010
2010 Patient and rheumatologist perspectives on glucocorticoids: An exercise to improve the implementation of the European League Against Rheumatism (EULAR) recommendations on the management of systemic glucocorticoid therapy in rheumatic diseasesAnnals of the Rheumatic Diseases.  69:1015-1021. 2010
2010 ReplyArthritis and Rheumatism.  62:1837-1838. 2010
2010 Using single-item health literacy screening questions to identify patients who read written nonsteroidal anti-inflammatory medicine information provided at pharmaciesJournal of Health Communication.  15:413-427. 2010
2010 Bone formation markers in patients with glucocorticoid-induced osteoporosis treated with teriparatide or alendronateBONE.  46:929-934. 2010
2010 (Journal of Rheumatology (2009) 36, (2114) DOI:10.3899/jrheum.090591)Journal of Rheumatology.  37:681. 2010
2010 The role of health literacy and written medicine information in nonsteroidal antiinflammatory drug risk awarenessAnnals of Pharmacotherapy.  44:274-284. 2010
2010 American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis.Arthritis Care and Research.  62:1515-1526. 2010
2010 Health literacy and happiness: A community-based studySocial Indicators Research.  95:325-338. 2010
2010 Impact of prevalent fractures on quality of life: Baseline results from the global longitudinal study of osteoporosis in womenMayo Clinic Proceedings.  85:806-813. 2010
2010 Is withholding osteoporosis medication after fracture sometimes rational? A Comparison of the risk for second fracture versus deathJournal of the American Medical Directors Association.  11:584-591. 2010
2009 Febuxostat: The evidence for its use in the treatment of hyperuricemia and goutCore Evidence.  4:25-36. 2009
2009 Health care expenditures associated with skeletal fractures among medicare beneficiaries, 1999-2005Journal of Bone and Mineral Research.  24:2050-2055. 2009
2009 "pathologic" fractures: Should these be included in epidemiologic studies of osteoporotic fractures?Osteoporosis International.  20:1969-1972. 2009
2009 Do physicians within the same practice setting manage osteoporosis patients similarly? Implications for implementation researchOsteoporosis International.  20:1921-1927. 2009
2009 Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: Thirty-six-month results of a randomized, double-blind, controlled trialArthritis and Rheumatism.  60:3346-3355. 2009
2009 Progress in osteoporosis and fracture prevention: Focus on postmenopausal womenArthritis Research.  11. 2009
2009 Quality health care gaps in osteoporosis: How can patients, providers, and the health system do a better job?Current Osteoporosis Reports.  7:27-34. 2009
2009 Clinical value of monitoring BMD in patients treated with bisphosphonates for osteoporosisJournal of Bone and Mineral Research.  24:1643-1646. 2009
2009 Estimated prevalence and patterns of presumed osteoporosis among older Americans based on Medicare dataOsteoporosis International.  20:1507-1515. 2009
2009 The geographic availability and associated utilization of dual-energy X-ray absorptiometry (DXA) testing among older persons in the United StatesOsteoporosis International.  20:1553-1561. 2009
2009 Gout. Hyperuricemia and cardiovascular disease: how strong is the evidence for a causal link?Arthritis Research.  11. 2009
2009 Once-weekly oral alendronate 70 mg in patients with glucocorticoid-induced bone loss: A 12-month randomized, placebo-controlled clinical trialJournal of Rheumatology.  36:1705-1714. 2009
2009 Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (health outcomes and reduced incidence with zoledronic acid once yearly trial): A multicentre, double-blind, double-dummy, randomized controlled trialObstetrical and Gynecological Survey.  64:521-523. 2009
2009 Editorial introductionsCurrent Opinion in Rheumatology.  21. 2009
2009 The Global Longitudinal Study of Osteoporosis in Women (GLOW): Rationale and study designOsteoporosis International.  20:1107-1116. 2009
2009 RisedronatE and ALendronate intervention over three years (REALITY): Minimal differences in fracture risk reductionOsteoporosis International.  20:973-978. 2009
2009 Health and happiness among older adults: A community-based studyJournal of Health Psychology.  14:503-512. 2009
2009 Vertebroplasty and kyphoplasty are associated with an increased risk of secondary vertebral compression fractures: A population-based cohort studyOsteoporosis International.  20:819-826. 2009
2009 Toward a Valid Definition of Gout Flare: Results of Consensus Exercises Using Delphi Methodology and Cognitive MappingArthritis Care and Research.  61:535-543. 2009
2009 Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trialLancet.  373:1253-1263. 2009
2009 Management of osteoporosis among home health and long-term care patients with a prior fractureSouthern Medical Journal.  102:397-404. 2009
2009 Improving the prediction of medication compliance: The example of bisphosphonates for osteoporosisMedical Care.  47:334-341. 2009
2009 To the EditorsArthritis Care and Research.  61:285-286. 2009
2009 ReplyArthritis Care and Research.  61:142. 2009
2009 Administrative codes combined with medical records based criteria accurately identified bacterial infections among rheumatoid arthritis patientsJournal of Clinical Epidemiology.  62. 2009
2009 Are glucocorticoids equivalent to NSAIDs for the treatment of gout flares?Nature Clinical Practice Rheumatology.  5:12-13. 2009
2009 Bridging the osteoporosis quality chasmJournal of Bone and Mineral Research.  24:3-7. 2009
2009 Glucocorticoids and the risk of osteoporosisExpert Opinion on Drug Safety.  8:33-47. 2009
2009 How to ascertain drug safety in the context of benefit. Controversies and concernsJournal of Rheumatology.  36:2114-2121. 2009
2009 Identification and validation of vertebral compression fractures using administrative claims dataMedical Care.  47:69-72. 2009
2009 Impact of Osteoporosis Treatment Adherence on Fracture Rates in North America and EuropeAmerican Journal of Medicine.  122:S3. 2009
2009 Patient-reported communications with pharmacy staff at community pharmacies: The Alabama NSAID Patient Safety Study, 2005-2007Journal of the American Pharmaceutical Association (Washington,D.C. : 1996).  49. 2009
2009 Population-based fracture risk assessment and osteoporosis treatment disparities by race and genderJournal of General Internal Medicine.  24:956-962. 2009
2009 Prediction of changes in bone mineral density in postmenopausal women treated with once-weekly bisphosphonatesJournal of Clinical Endocrinology and Metabolism.  94:1097-1103. 2009
2009 Strategies for treating rheumatoid arthritis: New guidelines from the ACRInternational Journal of Clinical Rheumatology.  4:3-5. 2009
2008 Serum urate, menopause, and postmenopausal hormone use: from eminence to evidence-based medicine.Arthritis Research.  10:120. 2008
2008 Effect of racial differences on ability to afford prescription medicationsAmerican Journal of Health-System Pharmacy.  65:2137-2143. 2008
2008 Management of Hyperuricemia and Gout in CKDAmerican Journal of Kidney Diseases.  52:994-1009. 2008
2008 Risk of hip fracture after bisphosphonate discontinuation: Implications for a drug holidayOsteoporosis International.  19:1613-1620. 2008
2008 The effect of thiazolidinediones on BMD and osteoporosis (Nature Clinical Practice Endocrinology and Metabolism (2008) 4, (507-513) DOI:10.1038/ ncpendmet0920)Nature Clinical Practice Endocrinology and Metabolism.  4:643. 2008
2008 Bisphosphonates for osteoarthritis prevention: "Holy Grail" or not?Annals of the Rheumatic Diseases.  67:1358-1359. 2008
2008 Regional Variation in the Denial of Reimbursement for Bone Mineral Density Testing Among US Medicare BeneficiariesJournal of Clinical Densitometry.  11:568-574. 2008
2008 Adaptation of bayesian data mining algorithms to longitudinal claims data: Coxib safety as an exampleMedical Care.  46:969-975. 2008
2008 Benefit of adherence with bisphosphonates depends on age and fracture type: Results from an analysis of 101,038 new bisphosphonate usersJournal of Bone and Mineral Research.  23:1435-1441. 2008
2008 Mortality and osteoporotic fractures: Is the link causal, and is it modifiable?Clinical and Experimental Rheumatology.  26. 2008
2008 Mortality and osteoporotic fractures: is the link causal, and is it modifiable?Clinical and Experimental Rheumatology.  26:S125-S137. 2008
2008 The effect of thiazolidinediones on BMD and osteoporosisNature Clinical Practice Endocrinology and Metabolism.  4:507-513. 2008
2008 Recommendations for use of selective and nonselective nonsteroidal antiinflammatory drugs: An American College of Rheumatology white paperArthritis Care and Research.  59:1058-1073. 2008
2008 Longitudinal trends in use of bone mass measurement among older Americans, 1999-2005Journal of Bone and Mineral Research.  23:1061-1067. 2008
2008 American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritisArthritis Care and Research.  59:762-784. 2008
2008 Association of infections and tuberculosis with antitumor necrosis factor alpha therapyCurrent Opinion in Rheumatology.  20:320-326. 2008
2008 Biologics and heart failure in rheumatoid arthritis: Are we any wiser?Current Opinion in Rheumatology.  20:327-333. 2008
2008 Drug Insight: Choosing a drug treatment strategy for women with osteoporosis - An evidence-based clinical perspectiveNature Clinical Practice Rheumatology.  4:240-248. 2008
2008 Improving quality of care in osteoporosis: Opportunities and challengesCurrent Rheumatology Reports.  10:123-130. 2008
2008 Teriparatide or alendronate in glucocorticoid-induced osteoporosisObstetrical and Gynecological Survey.  63:232-233. 2008
2008 The use of zoledronic acid for osteoporosis.Current Rheumatology Reports.  10:89-91. 2008
2008 Therapeutic advances in calcium and vitamin D for osteoporosis.Current Rheumatology Reports.  10:90-91. 2008
2008 The authors replyNew England Journal of Medicine.  358:1303-1304. 2008
2008 The epidemiology of glucocorticoid-associated adverse eventsCurrent Opinion in Rheumatology.  20:131-137. 2008
2008 Association of health-related quality of life with dual use of prescription and over-the-counter nonsteroidal antiinflammatory drugsArthritis Care and Research.  59:227-233. 2008
2008 Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronateJournal of Clinical Endocrinology and Metabolism.  93:3785-3793. 2008
2007 Racial/ethnic disparities in patient-reported nonsteroidal antiinflammatory drug (NSAID) risk awareness, patient-doctor NSAID risk communication, and NSAID risk behaviorArthritis Care and Research.  57:1539-1545. 2007
2007 Challenges in defining and improving osteoporosis quality of careClinical and Experimental Rheumatology.  25. 2007
2007 IntroductionClinical and Experimental Rheumatology.  25. 2007
2007 Drug-specific and time-dependent risks of bacterial infection among patients with rheumatoid arthritis who were exposed to tumor necrosis factor α antagonistsArthritis and Rheumatism.  56:4226-4227. 2007
2007 EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseasesAnnals of the Rheumatic Diseases.  66:1560-1567. 2007
2007 Teriparatide or alendronate in glucocorticoid-induced osteoporosisNew England Journal of Medicine.  357:2028-2039. 2007
2007 Challenges in defining and improving osteoporosis quality of care.Clinical and Experimental Rheumatology.  25:142-146. 2007
2007 Treatment of acute gout-like arthritis in an emergency setting: Prednisolone versus indomethacin: CommentaryNature Clinical Practice Rheumatology.  3:604-605. 2007
2007 Quality indicators for the care of osteoarthritis in vulnerable eldersJournal of the American Geriatrics Society.  55. 2007
2007 Randomized Trial to Improve Fracture Prevention in Nursing Home ResidentsAmerican Journal of Medicine.  120:886-892. 2007
2007 Mend the mind, but mind the bones! Balancing benefits and potential skeletal risks of serotonin reuptake inhibitorsArchives of Internal Medicine -New Series-.  167:1231-1232. 2007
2007 A single zoledronic acid infusion reduces bone resorption markers more rapidly than weekly oral alendronate in postmenopausal women with low bone mineral densityBONE.  40:1238-1243. 2007
2007 Denosumab in postmenopausal women with low bone mineral density.Current Rheumatology Reports.  9:48. 2007
2007 Effect of reproductive factors on rheumatoid arthritisFuture Rheumatology.  2:177-183. 2007
2007 Ibandronate injections in postmenopausal women with osteoporosis.Current Rheumatology Reports.  9:47. 2007
2007 New directions in osteoporosis therapy: Intravenous ibandronate and denosumabCurrent Rheumatology Reports.  9:47-49. 2007
2007 Prevalence and predictors of osteoporosis treatment in nursing home residents with known osteoporosis or recent fractureOsteoporosis International.  18:553-559. 2007
2007 Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor α antagonistsArthritis and Rheumatism.  56:1125-1133. 2007
2007 Challenges in improving the quality of osteoporosis care for long-term glucocorticoid users: A prospective randomized trialArchives of Internal Medicine -New Series-.  167:591-596. 2007
2007 Confirmation of administrative claims-identified opportunistic infections and other serious potential adverse events associated with tumor necrosis factor alpha antagonists and disease-modifying antirheumatic drugs.Arthritis and Rheumatism.  57:343-346. 2007
2007 Prevention and treatment of glucocorticoid-induced osteoporosisCurrent Osteoporosis Reports.  5:14-21. 2007
2007 Validity of gout diagnoses in administrative dataArthritis Care and Research.  57:103-108. 2007
2007 Heart failure among younger rheumatoid arthritis and Crohn's patients exposed to TNF-α antagonistsRheumatology.  46:1688-1693. 2007
2006 Osteoporosis in the home health care setting: A window of opportunity?Arthritis Care and Research.  55:971-975. 2006
2006 Treatment of rheumatoid arthritisAmerican Journal of Health-System Pharmacy.  63:2451-2465. 2006
2006 Improving the quality of clinical care for patients with osteoporosisExpert Review of Pharmacoeconomics and Outcomes Research.  6:641-645. 2006
2006 IntroductionAmerican Journal of Medicine.  119. 2006
2006 Agreement and validity of pharmacy data versus self-report for use of osteoporosis medications among chronic glucocorticoid usersPharmacoepidemiology and Drug Safety.  15:710-718. 2006
2006 Sex differences in gout epidemiology: Evaluation and treatmentAnnals of the Rheumatic Diseases.  65:1368-1372. 2006
2006 Pathophysiology, clinical presentation and treatment of goutDrugs.  66:1547-1563. 2006
2006 Racial or ethnic differences in allele frequencies of sinqle-nucleotide polymorphisms in the methylenetetrahydrofolate reductase gene and their influence on response to methotrexate in rheumatoid arthritisAnnals of the Rheumatic Diseases.  65:1213-1218. 2006
2006 Smoking interacts with genetic risk factors in the development of rheumatoid arthritis among older Caucasian womenAnnals of the Rheumatic Diseases.  65:1163-1167. 2006
2006 Channeling and adherence with alendronate and risedronate among chronic glucocorticoid usersOsteoporosis International.  17:1268-1274. 2006
2006 Osteoporotic fractures in older adultsBest Practice and Research: Clinical Rheumatology.  20:695-706. 2006
2006 Trends in prevention of glucocorticoid-induced osteoporosisJournal of Rheumatology.  33:1651-1657. 2006
2006 Comparison of weekly treatment of postmenopausal osteoporosis with alendronate versus risedronate over two yearsJournal of Clinical Endocrinology and Metabolism.  91:2631-2637. 2006
2006 Population-based assessment of adverse events associated with long-term glucocorticoid useArthritis Care and Research.  55:420-426. 2006
2006 Postmenopausal osteoporosis. What have we learned since the introduction of bisphosphonates?Reviews in Endocrine and Metabolic Disorders.  7:101-112. 2006
2006 Unbalanced regulation of over-the-counter analgesics: The lesser of two evils?Pharmacoepidemiology and Drug Safety.  15:410-411. 2006
2006 Is febuxostat a more effective treatment for hyperuricemia and gout than allopurinol? CommentaryNature Clinical Practice Rheumatology.  2:240-241. 2006
2006 Agreement between medical record documentation and patient-reported use of nonsteroidal antiinflammatory drugsAmerican Journal of Health-System Pharmacy.  63:744-747. 2006
2006 Epidemiology, risk factors, and lifestyle modifications for goutArthritis Research.  8. 2006
2006 Health-related quality of life among self-reported arthritis sufferers: Effects of race/ethnicity and residenceQuality of Life Research.  15:451-460. 2006
2006 Prevention of osteoporosis associated with chronic glucocorticoid therapy: CommentaryJournal of the American Medical Association.  295:1300-1303. 2006
2006 Medication errors with the use of allopurinol and colchicine: A retrospective study of a national, anonymous internet-accessible error reporting systemJournal of Rheumatology.  33:562-566. 2006
2006 New insights into gout epidemiologyCurrent Opinion in Rheumatology.  18:199-203. 2006
2006 Safety of low dose glucocorticoid treatment in rheumatoid arthritis: Published evidence and prospective trial dataAnnals of the Rheumatic Diseases.  65:285-293. 2006
2006 Ethnic variations in the prevalence of metabolic bone disease among HIV-positive patients with lipodystrophyAIDS Research and Human Retroviruses.  22:125-131. 2006
2006 Low-dose prednisolone in early rheumatoid arthritisCurrent Rheumatology Reports.  8:48-49. 2006
2006 The use of low-dose glucocorticoids for the treatment of early rheumatoid arthritis: What can we learn about bone effects of glucocorticoids from randomized controlled trials?Current Rheumatology Reports.  8:47-48. 2006
2006 Documented tuberculin skin testing among infliximab users following a multi-modal risk communication interventionsPharmacoepidemiology and Drug Safety.  15:11-18. 2006
2006 Gout medication treatment patterns and adherence to standards of care from a managed care perspectiveMayo Clinic Proceedings.  81:925-934. 2006
2006 Using a Modified Nominal Group Technique to Elicit Director of Nursing Input for an Osteoporosis InterventionJournal of the American Medical Directors Association.  7:420-425. 2006
2005 Fracture Reduction Affects Medicare Economics (FRAME): Impact of increased osteoporosis diagnosis and treatmentOsteoporosis International.  16:1545-1557. 2005
2005 A group randomized trial to improve safe use of nonsteroidal anti-inflammatory drugsAmerican Journal of Managed Care.  11:537-543. 2005
2005 Longitudinal patterns in the prevention of osteoporosis in glucocorticoid-treated patientsArthritis and Rheumatism.  52:2485-2494. 2005
2005 Prevalence of osteoporosis and osteopenia among African Americans with early rheumatoid arthritis: The impact of ethnic-specific normative dataJournal of the National Medical Association.  97:1155-1160. 2005
2005 Suboptimal physician adherence to quality indicators for the management of gout and asymptomatic hyperuricaemia: Results from the UK General Practice Research Database (GPRD)Rheumatology.  44:1038-1042. 2005
2005 The cost of glucocorticoid-associated adverse events in rheumatoid arthritisRheumatology.  44:781-788. 2005
2005 Racial disparities in the receipt of osteoporosis related healthcare among community-dwelling older women with arthritis and previous fractureJournal of Rheumatology.  32:870-875. 2005
2005 The molecular basis for the effectiveness, toxicity, and resistance to glucocorticoids: Focus on the treatment of rheumatoid arthritisScandinavian Journal of Rheumatology.  34:14-21. 2005
2005 Developments in glucocorticoid therapyRheumatic Disease Clinics of North America.  31:1-17. 2005
2005 Gout epidemiology: Results from the UK General Practice Research Database, 1990-1999Annals of the Rheumatic Diseases.  64:267-272. 2005
2005 Barriers to providing osteoporosis care in skilled nursing facilities: Perceptions of medical directors and directors of nursingJournal of the American Medical Directors Association.  6. 2005
2005 Gout treatment: what is evidence-based and how do we determine and promote optimized clinical care?Current Rheumatology Reports.  7:242-249. 2005
2005 Recent advances in the epidemiology of gout.Current Rheumatology Reports.  7:235-241. 2005
2004 Glucocorticoid use in rheumatoid arthritis: Benefits, mechanisms, and risksClinical and Experimental Rheumatology.  22. 2004
2004 Glucocorticoid use in rheumatoid arthritis: benefits, mechanisms, and risks.Clinical and Experimental Rheumatology.  22:S77-S82. 2004
2004 Evaluating and improving the quality of care in rheumatic diseaseExpert Review of Pharmacoeconomics and Outcomes Research.  4:429-439. 2004
2004 Measuring quality in arthritis care: The arthritis foundation's quality indicator set for analgesicsArthritis Care and Research.  51:337-349. 2004
2004 Prevention of glucocorticoid-induced osteoporosisSouthern Medical Journal.  97:555-558. 2004
2004 Measuring Quality in Arthritis Care: Methods for Developing the Arthritis Foundation's Quality Indicator SetArthritis Care and Research.  51:193-202. 2004
2004 Quality of Care Indicators for Gout ManagementArthritis and Rheumatism.  50:937-943. 2004
2004 Barriers to providing osteoporosis care in skilled nursing facilitities: Perceptions of Medical Directors and Directors of NursingJournal of the American Medical Directors Association.  5:361-366. 2004
2004 Incidence of hip osteonecrosis among renal transplantation recipients: A prospective studyClinical Radiology.  59:431-438. 2004
2004 Vitamin D Intake Is Inversely Associated With Rheumatoid Arthritis: Results From the Iowa Women's Health StudyArthritis and Rheumatism.  50:72-77. 2004
2003 Nonsteroidal Antiinflammatory Drug Toxicity Monitoring and Safety PracticesJournal of Rheumatology.  30:2680-2688. 2003
2003 Glucocorticoids in the treatment of early and late RAAnnals of the Rheumatic Diseases.  62:1033-1037. 2003
2003 The association of race/ethnicity with the receipt of traditional and alternative arthritis-specific health careMedical Care.  41:1233-1239. 2003
2003 Osteoporosis: Evaluation and treatmentCurrent Womens Health Reports.  3:418-424. 2003
2003 The effects of physician specialty and patient comorbidities on the use and discontinuation of coxibsArthritis Care and Research.  49:293-299. 2003
2003 Incidence of Nonvertebral Fractures in Relation to Time on Treatment and Bone Density in Glucocorticoid-Treated Patients: A Retrospective ApproachJCR: Journal of Clinical Rheumatology.  9:170-175. 2003
2003 Health related quality of life in women with elderly onset rheumatoid arthritisJournal of Rheumatology.  30:952-957. 2003
2003 Racial Disparities in Osteoporosis Prevention in a Managed Care PopulationSouthern Medical Journal.  96:445-451. 2003
2003 OMERACT 6 brings new perspectives to rheumatology measurement researchJournal of Rheumatology.  30:639-641. 2003
2003 Antioxidant micronutrients and risk of rheumatoid arthritis in a cohort of older womenAmerican Journal of Epidemiology.  157:345-354. 2003
2003 The Use of Glucocorticoids in Arthritis – 20 Clinical PearlsJournal of Musculoskeletal Medicine.  20:425-433. 2003
2003 Bone mineral density changes within six months of renal transplantationTransplantation.  75:49-54. 2003
2003 Bone mineral density changes within six months of renal transplantation.Transplantation.  75:49-54. 2003
2003 Balancing bones and bucks among new glucocorticoid usersJournal of Rheumatology.  30:1-3. 2003
2003 Estrogen and Other Female Reproductive Risk Factors Are Not Strongly Associated With the Development of Rheumatoid Arthritis in Elderly WomenSeminars in Arthritis and Rheumatism.  33:72-82. 2003
2003 Glucocorticoid-induced osteoporosisEndocrinology and Metabolism Clinics of North America.  32:135-157. 2003
2002 Intolerance to caffeine may increase susceptibility to rheumatoid arthritis: Comment on the article by Mikuls et al [3] (multiple letters)Arthritis and Rheumatism.  46:3104-3105. 2002
2002 Health-related quality of life in Gulf War era military personnelAmerican Journal of Epidemiology.  155:899-907. 2002
2002 Cigarette smoking and the risk of rheumatoid arthritis among postmenopausal women: Results from the Iowa Women's Health StudyAmerican Journal of Medicine.  112:465-471. 2002
2002 Coffee, tea, and caffeine consumption and risk of rheumatoid arthritis: Results from the Iowa women's health studyArthritis and Rheumatism.  46:83-91. 2002
2002 Blood transfusion, alcohol use, and anthropometric risk factors for rheumatoid arthritis in older womenJournal of Rheumatology.  29:246-254. 2002
2002 Coffee, tea, and caffeine consumption and risk of rheumatoid arthritis: results from the Iowa Women's Health Study.Arthritis and Rheumatism.  46:83-91. 2002
2002 Efficacy of tacrolimus in rheumatoid arthritis patients who have been treated unsuccessfully with methotrexate: A six-month, double-blind, randomized, dose-ranging studyArthritis and Rheumatism.  46:2020-2028. 2002
2002 Glucocorticoid therapy for arthritis: Overcoming the problemsDrug Benefit Trends.  14:39-43+52. 2002
2002 Glucocorticoid use in rheumatoid arthritis.Current Rheumatology Reports.  4:218-225. 2002
2002 Metabolic bone diseaseCurrent Opinion in Rheumatology.  14:404-405. 2002
2002 Mortality risk associated with rheumatoid arthritis in a prospective cohort of older women: Results from the Iowa Women's Health StudyAnnals of the Rheumatic Diseases.  61:994-999. 2002
2001 Protein-losing enteropathy in a young African-American woman with abdominal pain, diarrhea and hydronephrosisLupus.  10:835-840. 2001
2001 Samarium-153-EDTMP in the treatment of refractory rheumatoid arthritisScandinavian Journal of Rheumatology.  30:356-359. 2001
2001 Resolved: Low-dose glucocorticoids are neither safe nor effective for the long-term treatment of rheumatoid arthritisArthritis Care and Research.  45:468-471. 2001
2001 Use of complementary and alternative medicine by older patients with arthritis: A population-based studyArthritis Care and Research.  45:398-403. 2001
2001 Variations in glucocorticoid induced osteoporosis prevention in a managed care cohortJournal of Rheumatology.  28:1298-1305. 2001
2001 Comorbidity in rheumatoid arthritisRheumatic Disease Clinics of North America.  27:283-303. 2001
2001 Preferences for fractures and other glucocorticoid-associated adverse effects among rheumatoid arthritis patientsMedical Decision Making.  21:122-132. 2001
2001 Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 Update: American College of Rheumatology Ad Hoc Committee on glucocorticoid-induced osteoporosisArthritis and Rheumatism.  44:1496-1503. 2001
2001 Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: A randomized, double-blind, placebo-controlled extension trialArthritis and Rheumatism.  44:202-211. 2001
2001 Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial.Arthritis and Rheumatism.  44:202-211. 2001
2000 Erratum: Rofecoxib: A viewpoint by R.H. Hunt. Guest commentary (Drugs (1999) 58 (3) (506-507))Drugs.  59:179. 2000
2000 Moderate-term, low-dose corticosteroids for rheumatoid arthritis.Cochrane Database of Systematic Reviews2000
2000 Practice pattern variation among internal medicine specialists in the prevention of glucocorticoid-induced osteoporosisJCR: Journal of Clinical Rheumatology.  6:117-122. 2000
2000 Rofecoxib, a new cyclooxygenase 2 inhibitor, shows sustained efficacy, comparable with other nonsteroidal anti-inflammatory drugs: A 6-week and a 1-year trial in patients with osteoarthritisArchives of Family Medicine.  9:1124-1134. 2000
1999 Influenza and Pneumococcal Vaccine Receipt in Older Persons with Chronic Disease: A Population-Based StudyMedical Care.  37:502-509. 1999
1999 Epidemiology of glucocorticoid-induced osteoporosis concepts and controversiesJCR: Journal of Clinical Rheumatology.  5. 1999
1999 Rofecoxib. ViewpointsDrugs.  58:506-507. 1999
1998 Nonsteroidal anti-inflammatory drugs and cognitive function. Do they have a beneficial or deleterious effect?Drug Safety.  19:427-433. 1998
1998 Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosisNew England Journal of Medicine.  339:292-299. 1998
1998 Point of viewSpine.  23:838. 1998
1998 Arthritis health service utilization among the elderly: The role of urban-rural residence and other utilization factorsArthritis and Rheumatism.  11:177-185. 1998
1998 Arthritis health service utilization among the elderly: The role of urban-rural residence and other utilization factorsArthritis and Rheumatism.  11:177-185. 1998
1998 Variation in Tertiary Prevention and Health Service Utilization among the Elderly: The Role of Urban-Rural Residence and Supplemental InsuranceMedical Care.  36:965-976. 1998
1997 Low-dose corticosteroid therapy in rheumatoid arthritis: Balancing the evidenceAmerican Journal of Medicine.  103. 1997
1997 Low-dose corticosteroid therapy in rheumatoid arthritis: balancing the evidence.American Journal of Medicine.  103:31S-39S. 1997
1997 Health services researchCurrent Opinion in Rheumatology.  9:118-125. 1997
1997 Mixed connective tissue disease and radiation toxicity: A case reportCancer.  79:612-618. 1997
1997 Cigarette smoking and rheumatoid arthritis severityAnnals of the Rheumatic Diseases.  56:463-469. 1997
1996 Low-dose corticosteroids in rheumatoid arthritis: A meta-analysis of their moderate-term effectivenessArthritis and Rheumatism.  39:1818-1825. 1996
1996 Methotrexate patient education: A quality improvement studyArthritis and Rheumatism.  9:216-222. 1996
1996 Methotrexate patient education: A quality improvement studyArthritis and Rheumatism.  9:216-222. 1996
1996 Rheumatoid arthritis lung disease: Determinants of radiographic and physiologic abnormalitiesArthritis and Rheumatism.  39:1711-1719. 1996
1996 The foot function index for measuring rheumatoid arthritis pain: Evaluating side-to-side reliabilityFoot and Ankle International.  17:506-510. 1996
1995 Nonsteroidal antiinflammatory drugs and cognitive decline in the elderlyJournal of Rheumatology.  22:2142-2147. 1995
1995 Serious adverse events with low-dose, long-term corticosteroid therapy in rheumatoid arthritisAmerican Journal of Medicine.  99:692-693. 1995
1995 The replyAmerican Journal of Medicine.  99:693-694. 1995
1994 Nonsteroidal anti-inflammatory drugs. Balancing benefits and risks.Spine.  19:1530-1534. 1994
1994 Low dose long-term corticosteroid therapy in rheumatoid arthritis : an analysis of serious adverse eventsAm J Med.  96:115-123. 1994
1994 Low dose long-term corticosteroid therapy in rheumatoid arthritis: An analysis of serious adverse eventsAmerican Journal of Medicine.  96:115-123. 1994
1994 Spine update nonsteroidal anti-inflammatory drugs balancing benefits and risksSpine.  19:1530-1534. 1994
1993 Parvovirus Bl9-specific DNA in bone marrow from B19 arthropathy patients: Evidence for B19 virus persistenceJournal of Infectious Diseases.  167:744-748. 1993
1992 Subcutaneous pancreatic fat necrosis associated with acute arthritisJournal of Rheumatology.  19:630-632. 1992
1990 An eosinophilia-myalgia syndrome associated with an L-tryptophan containing productJournal of Rheumatology.  17:1551-1553. 1990
1989 Infectious Diarrhea Secondary to Enteromonas hominisAmerican Journal of Gastroenterology.  84:1313-1314. 1989

Book

Year Title Altmetric
2009 Preface.  Ed. 23.  2009

Chapter

Year Title Altmetric
2018 Glucocorticoid-induced osteoporosis.  467-473. 2018
2015 Systemic glucocorticoids in rheumatology.  423-433. 2015
2013 Epidemiology of gout.  7-23. 2013
2013 Glucocorticoid-Induced Osteoporosis.  1191-1223. 2013
2009 Osteoporosis.  393-404. 2009
2008 Glucocorticoid-Induced Osteoporosis.  1135-1166. 2008
2008 Osteoporosis A. epidemiology and clinical assessment.  576-583. 2008
2005 Prevention and Treatment 2005
2001 Glucocorticoid-induced osteoporosis.  140-145. 2001

Research Overview

  • Dr. Saag's current research focuses on the epidemiology of osteoporosis and rheumatoid arthritis as well as methods to translate evidence into practice for both arthritis and osteoporosis.
  • Principal Investigator On

  • Deep South Translational Research Mentored Career Development Program (CCTS)  awarded by National Center for Advancing Translational Sciences/NIH/DHHS 2019 - 2024
  • NRSA Training Core (CCTS)  awarded by National Center for Advancing Translational Sciences/NIH/DHHS 2019 - 2024
  • T32 In Health Services Research Training Program  awarded by Agency for Healthcare Research and Quality/DHHS 2018 - 2023
  • Private Grant  awarded by HORIZON PHARMA USA, INC. 2017 - 2022
  • CF Admin Core (Old) to New  awarded by National Institute of Arthritis & Musculoskeletal & Skin Diseases/NIH/DHHS 2017 - 2022
  • CF Project 2 (Old) to New  awarded by National Institute of Arthritis & Musculoskeletal & Skin Diseases/NIH/DHHS 2017 - 2022
  • CF Project 3 (OLD) to new  awarded by National Institute of Arthritis & Musculoskeletal & Skin Diseases/NIH/DHHS 2017 - 2022
  • CF Project 4 (OLD) to new  awarded by National Institute of Arthritis & Musculoskeletal & Skin Diseases/NIH/DHHS 2017 - 2022
  • INvestigations In Gout, Hyperuricemia, and ComorbidiTies (INSIGHT) Center of Research Translation (CORT)  awarded by National Institute of Arthritis & Musculoskeletal & Skin Diseases/NIH/DHHS 2017 - 2022
  • INvestigations In Gout, Hyperuricemia, and ComorbidiTies (INSIGHT) Center of Research Translation (CORT) - Administrative Core  awarded by National Institute of Arthritis & Musculoskeletal & Skin Diseases/NIH/DHHS 2017 - 2022
  • INvestigations In Gout, Hyperuricemia, and ComorbidiTies (INSIGHT) Center of Research Translation (CORT) - Improving Minority Gout Care and Clinical Research Participation in the Southeast  awarded by National Institute of Arthritis & Musculoskeletal & Skin Diseases/NIH/DHHS 2017 - 2022
  • INvestigations In Gout, Hyperuricemia, and ComorbidiTies (INSIGHT) Center of Research Translation (CORT) - Project 1: AMPK and Inflammation in Gout  awarded by National Institute of Arthritis & Musculoskeletal & Skin Diseases/NIH/DHHS 2017 - 2022
  • INvestigations In Gout, Hyperuricemia, and ComorbidiTies (INSIGHT) Center of Research Translation (CORT) - Project 2: Novel Risk Factors and Precision Medicine for Gout Flares  awarded by National Institute of Arthritis & Musculoskeletal & Skin Diseases/NIH/DHHS 2017 - 2022
  • INvestigations In Gout, Hyperuricemia, and ComorbidiTies (INSIGHT) Center of Research Translation (CORT) - Project 3: Translational Genomics of Hyperuricemia  awarded by National Institute of Arthritis & Musculoskeletal & Skin Diseases/NIH/DHHS 2017 - 2022
  • Private Grant  awarded by AMPEL BIOSOLUTIONS 2016 - 2021
  • Strengthening Translational Research in Diverse Enrollment (STRIDE)  awarded by UNIVERSITY OF MASSACHUSETTS (WORCESTER) 2016 - 2021
  • Private Grant  awarded by MEREO BIOPHARMA 3 LIMITED 2017 - 2020
  • Private Grant  awarded by KIBOW BIOTECH 2019 - 2020
  • Private Grant  awarded by RADIUS HEALTH 2018 - 2020
  • Private Grant  awarded by SHANTON PHARMA CO. LTD 2019 - 2020
  • National Resource Center for High-Impact Clinical Trials in Medical Rehabilitation: Promo/Dissemination Component  awarded by National Institute of Child Health and Human Development/NIH/DHHS 2015 - 2020
  • Private Grant  awarded by AMGEN, INC. 2018 - 2020
  • REduCing Immunogenicity to PegloticasE (RECIPE)  awarded by National Institute of Arthritis & Musculoskeletal & Skin Diseases/NIH/DHHS 2018 - 2020
  • Private Grant  awarded by SWEDISH ORPHAN BIOVITRUM AB 2017 - 2020
  • UAB Center for Clinical and Translational Science (CCTS) (TL1)  awarded by National Center for Advancing Translational Sciences/NIH/DHHS 2015 - 2019
  • UAB Center for Clinical and Translational Science (CCTS) (KL2)  awarded by National Center for Advancing Translational Sciences/NIH/DHHS 2015 - 2019
  • UAB K12 in Patient Centered Outcomes Research  awarded by Agency for Healthcare Research and Quality/DHHS 2014 - 2019
  • Private Grant  awarded by HORIZON PHARMA USA, INC. 2017 - 2019
  • Private Grant  awarded by ACTIVE LIFE SCIENTIFIC, INC. 2018 - 2019
  • Private Grant  awarded by ASTRAZENECA PHARMACEUTICALS LP 2016 - 2019
  • UAB Health Services, Outcomes, and Effectiveness Research Training Program  awarded by Agency for Healthcare Research and Quality/DHHS 2013 - 2018
  • Private Grant  awarded by TAKEDA GLOBAL RESEARCH & DEVELOPMENT CENTER 2010 - 2018
  • Private Grant  awarded by AMGEN, INC. 2012 - 2018
  • Private Grant  awarded by AMGEN, INC. 2012 - 2018
  • Centers of Research Translation (CoRT)  awarded by National Institute of Arthritis & Musculoskeletal & Skin Diseases/NIH/DHHS 2012 - 2017
  • Centers of Research Translation (CoRT) - Project 2  awarded by National Institute of Arthritis & Musculoskeletal & Skin Diseases/NIH/DHHS 2012 - 2017
  • Centers of Research Translation (CoRT) - Administrative Core  awarded by National Institute of Arthritis & Musculoskeletal & Skin Diseases/NIH/DHHS 2012 - 2017
  • UAB Deep South Arthritis and Musculoskeletal CERTs  awarded by Agency for Healthcare Research and Quality/DHHS 2011 - 2017
  • Activating Patients to Reduce Osteoporosis (APROPOS)  awarded by National Institute of Arthritis & Musculoskeletal & Skin Diseases/NIH/DHHS 2011 - 2017
  • Patient-Centered Outcomes Research Translation Center  awarded by Baylor University 2016 - 2017
  • Private Grant  awarded by SAVIENT PHARMACEUTICALS 2012 - 2017
  • Private Grant  awarded by ARDEA BIOSCIENCES, INC. 2013 - 2017
  • Private Grant  awarded by ELI LILLY AND COMPANY 2014 - 2016
  • Private Grant  awarded by HORIZON PHARMA USA, INC. 2016
  • Pilot Studies for the Active Comparator Osteoporosis Large Simple Trial (ATLAST)  awarded by National Institute of Arthritis & Musculoskeletal & Skin Diseases/NIH/DHHS 2012 - 2016
  • Effectiveness of DiscontinuinG BisphosphonatEs Study (EDGE)  awarded by National Institute of Arthritis & Musculoskeletal & Skin Diseases/NIH/DHHS 2013 - 2016
  • A Patient Activation Intervention to Improve Bone Health in Older Adults  awarded by University of Iowa 2010 - 2016
  • Private Grant  awarded by TAKEDA DEVELOPMENT CENTER AMERICAS, INC. 2015 - 2016
  • Private Grant  awarded by TAKEDA DEVELOPMENT CENTER AMERICAS, INC. 2014 - 2016
  • Private Grant  awarded by CREALTA PHARMACEUTICALS, LLC - NEW 2015 - 2016
  • Mid-Career Investigator Award  awarded by National Institute of Arthritis & Musculoskeletal & Skin Diseases/NIH/DHHS 2010 - 2015
  • Patient Centered Outcomes Research Institutional Award (K12)  awarded by Agency for Healthcare Research and Quality/DHHS 2012 - 2014
  • Private Grant  awarded by ARDEA BIOSCIENCES, INC. 2012 - 2014
  • Private Grant  awarded by ARDEA BIOSCIENCES, INC. 2013 - 2014
  • NIAMS Multidiscipllinary Clinical Research Center - Project 4  awarded by National Institute of Arthritis & Musculoskeletal & Skin Diseases/NIH/DHHS 2008 - 2014
  • Private Grant  awarded by REGENERON PHARMACEUTICALS, INC. 2012 - 2014
  • Private Grant  awarded by ARDEA BIOSCIENCES, INC. 2012 - 2013
  • Private Grant  awarded by TAKEDA GLOBAL RESEARCH & DEVELOPMENT CENTER 2010 - 2013
  • Private Grant  awarded by MERCK & COMPANY, INC. 2009 - 2013
  • Private Grant  awarded by ARDEA BIOSCIENCES, INC. 2011 - 2013
  • UAB K12 in Comparative Effectiveness Research  awarded by Agency for Healthcare Research and Quality/DHHS 2010 - 2013
  • UAB T32 in Comparative Effectiveness Research  awarded by Agency for Healthcare Research and Quality/DHHS 2010 - 2013
  • UAB Health Services & Outcomes Research Training Program  awarded by Agency for Healthcare Research and Quality/DHHS 2009 - 2013
  • Detection and Analysis of Adverse Events Related to Regulated Products in Automated Healthcare Data. Efforts to Develop the Sentinel Initiative  awarded by HARVARD PILGRIM HEALTH CARE 2011 - 2012
  • The Global Longitudinal Registry of Osteoporosis in Women (GLOW)  awarded by UNIVERSITY OF MASSACHUSETTS (WORCESTER) 2006 - 2012
  • Deep South Musculoskeletal Certs (DSMC)  awarded by Agency for Healthcare Research and Quality/DHHS 2007 - 2012
  • Private Grant  awarded by Procter & Gamble Company 2008 - 2012
  • Private Grant  awarded by AMGEN, INC. 2009 - 2012
  • Private Grant  awarded by MERCK & COMPANY, INC. 2009 - 2011
  • Private Grant  awarded by Sanofi US Services Inc 2009 - 2011
  • Private Grant  awarded by TAKEDA GLOBAL RESEARCH & DEVELOPMENT CENTER 2010 - 2011
  • Improving Bone Health Among RA Patients on Chronic Glucocorticoids  awarded by American College of Rheumatology 2008 - 2011
  • Private Grant  awarded by ELI LILLY AND COMPANY 2004 - 2011
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION 2010 - 2011
  • Private Grant  awarded by REGENERON PHARMACEUTICALS, INC. 2009 - 2011
  • Private Grant  awarded by AMGEN, INC. 2010
  • Investigator On

  • Center for Clinical and Translational Science (3 Linked Awards UL1, KL2, TL1)  awarded by National Center for Advancing Translational Sciences/NIH/DHHS 2019 - 2024
  • INvestigations In Gout, Hyperuricemia, and ComorbidiTies (INSIGHT) Center of Research Translation (CORT)  awarded by National Institute of Arthritis & Musculoskeletal & Skin Diseases/NIH/DHHS 2017 - 2022
  • INvestigations In Gout, Hyperuricemia, and ComorbidiTies (INSIGHT) Center of Research Translation (CORT) - Project 4: Protecting Renal Function with Urate-Lowering Drugs  awarded by National Institute of Arthritis & Musculoskeletal & Skin Diseases/NIH/DHHS 2017 - 2022
  • UAB Research and Education Program in Neuroscience  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS 2017 - 2022
  • Implementation of DEcision-Aid for Lupus in Practice Settings for Shared Decision-Making (SOM): IDEAL Study  awarded by PATIENT CENTERED OUTCOMES RESEARCH INSTITUTE 2018 - 2021
  • Biology or Management: Understanding Racial Differences in Post Fracture Outcomes  awarded by National Institute of Arthritis & Musculoskeletal & Skin Diseases/NIH/DHHS 2017 - 2021
  • Training Program in Rheumatic and Musculoskeletal Diseases Research  awarded by National Institute of Arthritis & Musculoskeletal & Skin Diseases/NIH/DHHS 2016 - 2021
  • National Resource Center for High-Impact Clinical Trials in Medical Rehabilitation: Admin Oversight Component  awarded by National Institute of Child Health and Human Development/NIH/DHHS 2015 - 2020
  • National Resource Center for High-Impact Clinical Trials in Medical Rehabilitation: Coordinating Center  awarded by National Institute of Child Health and Human Development/NIH/DHHS 2015 - 2020
  • Rehabilitation Research Resource to Enhance Clinical Trials (REACT)  awarded by National Institute of Child Health and Human Development/NIH/DHHS 2015 - 2020
  • DNA Sequencing for Newborn Nurseries in the South  awarded by HUDSONALPHA INSTITUTE FOR BIOTECHNOLOGY 2017 - 2020
  • Private Grant  awarded by AMGEN, INC. 2016 - 2019
  • Skeletal Health in Bariatric Surgery Patients  awarded by American Society for Metabolic and Bariatric Surgery Foundation 2017 - 2019
  • UAB Center for Clinical and Translational Science (CCTS) (3 Linked Awards UL1, KL2, TL1)  awarded by National Center for Advancing Translational Sciences/NIH/DHHS 2015 - 2019
  • UAB Multidisciplinary Clinical Research Center (P60)  awarded by National Institute of Arthritis & Musculoskeletal & Skin Diseases/NIH/DHHS 2013 - 2019
  • UAB Multidisciplinary Clinical Research Center - Core A (Administrative Core)  awarded by National Institute of Arthritis & Musculoskeletal & Skin Diseases/NIH/DHHS 2013 - 2019
  • Targeting the Interactions Between Disordered Iron Homeostasis and Mineral Metabolism in Chronic Kidney Disease to Improve Cardiovascular Outcomes  awarded by American Heart Association 2017 - 2018
  • Individualized Patient Decision Making for Treatment Choices Among Minorities with Lupus  awarded by PATIENT CENTERED OUTCOMES RESEARCH INSTITUTE 2013 - 2018
  • Private Grant  awarded by O.N. DIAGNOSTICS, LLC 2015 - 2017
  • Centers of Research Translation (CoRT)  awarded by National Institute of Arthritis & Musculoskeletal & Skin Diseases/NIH/DHHS 2012 - 2017
  • UAB Research and Education Program in Neurology, Neurosurgery, and Neuropathology  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS 2012 - 2017
  • Private Grant  awarded by Janssen 2016 - 2017
  • PROs in Inflammatory Arthritis: Electronic Capture to Improve Patient Outcomes  awarded by RHEUMATOLOGY RESEARCH FOUNDATION 2014 - 2017
  • A Pilot Study of the Safety and Effectiveness of the Live Zoster Vaccine in Anti-TNF Users  awarded by RHEUMATOLOGY RESEARCH FOUNDATION 2013 - 2016
  • Private Grant  awarded by ABBVIE INC 2016
  • Arthritis Patient Partnership With Comparative Effectiveness Researchers (AR-Power PPRN)  awarded by GLOBAL HEALTHY LIVING FOUNDATION 2014 - 2015
  • UAB Center for Clinical and Translational Science (CCTS) (3 linked awards: UL1, KL2, TL1)  awarded by National Center for Advancing Translational Sciences/NIH/DHHS 2014 - 2015
  • Longitudinal Comparative Effectiveness & Safety of Biologics in Autoimmunity  awarded by Agency for Healthcare Research and Quality/DHHS 2009 - 2014
  • Burden of Osteoporosis and Low Bone Density in the United States  awarded by National Osteoporosis Foundation 2012 - 2014
  • NIAMS Multidiscipllinary Clinical Research Center  awarded by National Institute of Arthritis & Musculoskeletal & Skin Diseases/NIH/DHHS 2008 - 2014
  • NIAMS Multidiscipllinary Clinical Research Center - Administrative Core  awarded by National Institute of Arthritis & Musculoskeletal & Skin Diseases/NIH/DHHS 2008 - 2014
  • UAB Center for Clinical and Translational Science (CCTS) KL2 Component  awarded by National Center for Advancing Translational Sciences/NIH/DHHS 2011 - 2014
  • UAB Center for Clinical and Translational Science (CCTS) UL1  awarded by National Center for Advancing Translational Sciences/NIH/DHHS 2011 - 2014
  • Using CERs to Optimize Quality of Life for Persons with Diabetes and Chronic Pain  awarded by Agency for Healthcare Research and Quality/DHHS 2010 - 2013
  • Comprehensive Minority and Health Disparities Research Center - ARRA Supplement  awarded by NATIONAL INSTITUTE ON MINORITY HEALTH AND HEALTH DISPARITIES/NIH/DHHS 2010 - 2012
  • Comprehensive Minority and Health Disparities Research Center  awarded by NATIONAL INSTITUTE ON MINORITY HEALTH AND HEALTH DISPARITIES/NIH/DHHS 2007 - 2012
  • Ethnic Differences in the Risk of Fracture and Vascular Disease  awarded by National Institute of Arthritis & Musculoskeletal & Skin Diseases/NIH/DHHS 2007 - 2012
  • Private Grant  awarded by AMGEN, INC. 2010 - 2012
  • Education And Training

  • Master of Science in Epidemiology, University of Iowa 1993
  • Doctor of Medicine, Northwestern University 1986
  • Northwestern Memorial Hospital, Residency 1990
  • University of Iowa Hospitals and Clinics, Postdoctoral Fellowship 1993
  • Full Name

  • Kenneth Saag